Pancragen
A synthetic tetrapeptide bioregulator (Lys-Glu-Asp-Trp) from the Khavinson system, studied for pancreatic function, glucose metabolism, and age-related type 2 diabetes.
What is Pancragen?
Pancragen is a synthetic tetrapeptide consisting of lysine, glutamic acid, aspartic acid, and tryptophan (Lys-Glu-Asp-Trp, or KEDW), developed by Vladimir Khavinson as part of his bioregulator peptide system. It targets pancreatic tissue — both the insulin-producing beta cells and the enzyme-secreting acinar cells. With 8 PubMed-indexed publications including human clinical data and primate studies, it is one of the better-characterized Khavinson bioregulators. A clinical study in elderly type 2 diabetes patients showed significant reductions in fasting glucose and insulin resistance, and primate studies demonstrated it outperformed glimepiride in normalizing insulin secretion.
What Pancragen Is Investigated For
Pancragen is a synthetic Khavinson tetrapeptide (Lys-Glu-Asp-Trp) targeted at pancreatic tissue, studied for age-related type 2 diabetes, glucose tolerance improvement, insulin resistance reduction, and restoration of beta-cell function. Within the Khavinson catalog, it is one of the better-characterized entries: eight PubMed-indexed publications include a 33-patient elderly T2D clinical study reporting reduced fasting glucose and insulin resistance, rhesus monkey work showing normalized insulin and C-peptide responses, and cell-culture data on pancreatic transcription-factor upregulation (PDX1, NGN3, PAX6). The strongest signal is in the aged-primate insulin-normalization data, where Pancragen outperformed glimepiride. However, the clinical evidence remains small-sample Russian research, methodology details do not consistently meet Western trial standards, and independent replication outside the Khavinson program is essentially absent. Critically, any diabetic patient considering Pancragen must remain under endocrinology supervision — uncoordinated combination with insulin or sulfonylureas could produce hypoglycemia, and Pancragen is not a substitute for prescribed diabetes medication.
History & Discovery
Pancragen was developed by Vladimir Khavinson's bioregulator program at the St. Petersburg Institute of Bioregulation and Gerontology, in the same broader effort that produced the cortex, pineal, thymus, and cartilage tetrapeptides. The natural-extract counterpart in this lineage is Suprefort, a peptide complex from animal pancreatic tissue. Pancragen (Lys-Glu-Asp-Trp, KEDW) was synthesized as a chemically defined short-peptide counterpart, with the hypothesis that the tetrapeptide retains the pancreas-specific regulatory effects of the larger natural preparation in a more standardized form. With eight PubMed-indexed publications including a 33-patient elderly type-2-diabetes study and rhesus monkey work, Pancragen is one of the better-characterized entries in the Khavinson catalog. Reported findings include improved glucose tolerance and reduced insulin resistance in elderly diabetic patients, normalized insulin and C-peptide responses in aged primates, and upregulation of pancreatic transcription factors (PDX1, NGN3, PAX6) in cell culture. As with the rest of the Khavinson program, however, this evidence is concentrated in a single research lineage, the human study is small, blinding and randomization standards do not consistently meet modern Western trial methodology, and independent Western replication of any of the core findings is essentially absent. The clinical claims for type-2-diabetes management substantially exceed what an independent reviewer would conclude from the available evidence.
How It Works
Pancragen is a four-amino-acid peptide that targets pancreatic cells. It is proposed to enter cell nuclei and activate genes responsible for insulin production and pancreatic cell maintenance. In aging, these genes can become less active — Pancragen may help restore their function, improving the pancreas's ability to regulate blood sugar.
Pancragen (Lys-Glu-Asp-Trp) is proposed to bind directly to DNA along the major groove, forming stable peptide-DNA complexes that regulate transcription of pancreatic genes. It increases expression of key pancreatic transcription factors including PDX1, NGN3, PAX6, FOXA2, NKX2-2, NKX6.1, and PAX4 — fundamental regulators of beta-cell development and function. In aging pancreatic cultures, it enhances expression of MMP2, MMP9, serotonin, and CD79alpha while reducing apoptosis markers, indicating both functional stimulation and cell survival effects. It also stimulates differentiation factors in acinar and islet cells, with effects more pronounced in aged tissue. In diabetic rat models, oral administration produced hypoglycemic effects while injection normalized endothelial adhesion in mesenteric capillaries, suggesting both metabolic and vascular protective mechanisms.
Evidence Snapshot
Human Clinical Evidence
Limited but promising. A study of 33 elderly patients with type 2 diabetes showed Pancragen significantly decreased fasting glucose, improved glucose tolerance, and reduced insulin resistance, while also noting that nocturnal melatonin production was reduced 70% in diabetic patients (PMID: 22448364). No Western clinical trials are indexed.
Animal / Preclinical
Moderate. In old rhesus monkeys, Pancragen improved glucose clearance and normalized insulin/C-peptide responses, with benefits persisting 3 weeks post-treatment (PMID: 25946840). It outperformed glimepiride in normalizing insulin secretion in aged primates (PMID: 28509500). Oral Pancragen produced pronounced hypoglycemic effects in diabetic rats and normalized endothelial adhesion (PMID: 18642713). In vitro, it enhanced pancreatic cell differentiation markers in aged cultures (PMID: 23486591, 23734516).
Mechanistic Rationale
Moderate. Multiple studies demonstrate specific effects on pancreatic gene expression: upregulation of key beta-cell transcription factors (PDX1, NGN3, PAX6), stimulation of differentiation markers (MMP2, MMP9, serotonin), and anti-apoptotic effects. The proposed DNA-binding mechanism is consistent with the broader Khavinson framework.
Research Gaps & Open Questions
What the current literature has not yet settled about Pancragen:
- 01Independent replication outside the Khavinson research program — the human study and primate findings have not been reproduced by Western laboratories under modern trial-methodology standards.
- 02Larger blinded randomized controlled trials in humans for type-2-diabetes management — the existing 33-patient study is too small to support clinical conclusions and methodology details are not transparent.
- 03Pharmacokinetics in humans — absorption (particularly oral and sublingual bioavailability of the intact tetrapeptide), distribution to pancreatic tissue, and clearance have not been characterized.
- 04Mechanism specificity — direct DNA interaction by a tetrapeptide and the resulting pancreas-specific transcription-factor activation claim has not been independently validated.
- 05Long-term safety with cumulative repeated courses, including any effects on pancreatic-cell proliferation that could become problematic with chronic use or in subclinical malignancy.
- 06Combination safety and efficacy with standard diabetes medications — Pancragen has not been formally studied as adjunctive therapy alongside insulin, sulfonylureas, metformin, or GLP-1 agonists.
Forms & Administration
Pancragen is available in capsule, sublingual, and injectable formats. In primate studies, intramuscular injection of 50 mcg/day for 10 days was used. Capsule protocols typically involve 1-2 capsules daily for 10-30 days. All peptides should only be used under the guidance of a qualified healthcare provider. Never self-administer without clinician oversight.
Dosing & Protocols
The ranges below reflect protocols commonly discussed in the literature and by clinicians — not a prescription. Actual dosing for any individual should be determined by a qualified healthcare provider who knows the patient.
Typical Range
Published primate studies used 50 mcg/day intramuscular injection. Russian Khavinson-affiliated capsule products typically deliver low milligram-range doses formulated for sublingual or oral administration. Research-chemical injectable Pancragen is sold for SC use at 100–200 mcg per dose. There is no published independent dose-finding study in humans.
Frequency
Daily administration during the course — typically 1–2 capsules per day for oral forms, or once-daily SC or IM injection for injectable forms.
Timing Considerations
No specific timing requirements: can be administered at any time of day, with or without food, and is not tied to exercise timing. Consistency matters more than the specific clock — dose at roughly the same time each day (or same day each week, for weekly protocols) to keep exposure steady.
Cycle Length
10–30 day courses repeated every 3–6 months — a characteristic feature of Khavinson protocols. The published primate study used 10 days of dosing followed by extended observation. Continuous long-term daily use is not part of the published Khavinson regimen.
Protocol Notes
Russian Khavinson-affiliated capsule and sublingual products are sold as dietary peptide complexes (Peptides.ru and similar brands) rather than registered pharmaceuticals. Research-chemical injectable Pancragen is supplied as lyophilized powder requiring reconstitution in bacteriostatic water. Western clinicians do not generally prescribe Pancragen; protocols outside Russia rely on convention rather than anchored clinical guidance. Critically: any patient with diagnosed diabetes considering Pancragen must monitor blood glucose carefully and remain under endocrinology supervision — Pancragen is not a substitute for prescribed diabetes medication, and uncoordinated combination with insulin or sulfonylureas could produce hypoglycemia.
Claims for type-2-diabetes management, beta-cell restoration, and metabolic improvement exceed what the evidence base — a single small human study and primate data from one program — can independently support. Not FDA-approved. Russian protocols come from a single-lab tradition not validated by Western-standard trials. Pancragen is not a substitute for prescribed diabetes medication. Research-chemical injectable supply is not authorized for human use.
Timeline of Effects
Onset
Not rigorously characterized. The published 33-patient diabetic study reports glucose and insulin parameter changes over a treatment course; subjective metabolic effects, when reported by users, are typically described within the first 1–2 weeks of a course.
Peak Effect
Khavinson and primate-study protocols measure outcomes at the end of a 10-day course and at follow-up. The primate study reported persistence of normalized insulin/C-peptide responses 3 weeks post-treatment. Peak effect for individual users is not well characterized.
After Discontinuation
No documented withdrawal or rebound. Primate data suggests measurable effects persisting at least 3 weeks post-course; longer-term persistence has not been characterized. The periodic-repeat-course schedule reflects an assumption that effects fade and need to be reinforced. Sudden discontinuation in a patient also taking insulin or sulfonylureas could produce glucose dysregulation if Pancragen had been contributing to glycemic control — coordinated medical supervision is essential.
Common Questions
Who Pancragen Is NOT For
- •Pregnancy — no adequate reproductive toxicology data; not recommended.
- •Breastfeeding — no data on transfer or infant effects.
- •Concurrent insulin or sulfonylurea therapy without endocrinology supervision — Pancragen's reported insulin-sensitizing or beta-cell-stimulating effects could potentiate hypoglycemia from those agents.
- •Active or recent-history pancreatic malignancy — agents proposed to stimulate pancreatic cell proliferation and gene expression are theoretically concerning in pancreatic tumor contexts and warrant oncology clinician input.
- •Pediatric use — no safety or developmental data; not recommended.
- •Known hypersensitivity to peptide preparations or to excipients. Research-chemical injectable supply quality and unknown sterility raise injection-site infection risk absent from clinic-supplied medication.
Drug & Supplement Interactions
Documented clinical drug interactions for Pancragen are essentially absent; no formal interaction studies meeting Western standards have been published. The most clinically meaningful theoretical concern is with anti-diabetic medication: insulin, sulfonylureas (glyburide, glipizide, glimepiride), and meglitinides could be potentiated if Pancragen contributes to glucose lowering, raising hypoglycemia risk in uncoordinated combination. The published primate study positioned Pancragen as mechanistically distinct from glimepiride (acting on beta-cell function rather than on potassium channels), but functional combination has not been formally studied. Concurrent use with metformin, GLP-1 agonists, SGLT2 inhibitors, or DPP-4 inhibitors has not been studied either. Combination with other Khavinson bioregulators is common in forum culture but unstudied. Patients on any diabetes medication, hormonal therapy, or oncology-related treatment should disclose Pancragen use to their prescribing clinician.
Safety Profile
Common Side Effects
Cautions
- • Not FDA-approved
- • Clinical data from small sample sizes
- • May affect blood glucose — requires monitoring in diabetic patients
- • Should be used under clinician guidance
What We Don't Know
Western clinical trial data is absent. Human data comes from a single study of 33 type 2 diabetes patients. Long-term effects and interactions with diabetes medications have not been systematically evaluated.
Legal Status
United States
Not FDA-approved for any indication. Not recognized as a dietary supplement ingredient. Not on the FDA's list of peptides eligible for 503A compounding. Injectable forms sold primarily through research-chemical suppliers not authorized for human use. Russian capsule products are sometimes imported informally; legitimate clinical access pathways are essentially absent.
International
Russian Khavinson-affiliated capsule and sublingual products are marketed as dietary peptide complexes under brands like Peptides.ru. Limited availability through informal CIS distribution. Not approved by EMA, MHRA, Health Canada, or TGA.
Sports & Competition
Not specifically named on the WADA Prohibited List. As an unapproved substance for therapeutic use in most WADA-code jurisdictions, the WADA S0 catch-all category likely applies to injectable forms. Athletes subject to WADA code should treat injectable Pancragen as prohibited.
Regulatory status changes over time. Verify current local rules with a qualified professional.
Myths & Misconceptions
Myth
Pancragen can replace insulin or other prescribed diabetes medication.
Reality
It cannot, and treating it as a substitute is dangerous. The available evidence consists of a single small Russian study plus primate work; it does not establish Pancragen as a stand-alone treatment for type-2 diabetes, let alone for type-1 diabetes where insulin replacement is essential. Discontinuing prescribed diabetes medication in favor of Pancragen risks serious hyperglycemic events.
Myth
Pancragen has been proven superior to standard diabetes medications.
Reality
It has not. The primate-study comparison with glimepiride is a single small preclinical comparison from the originating research program; it is not equivalent to a head-to-head clinical trial in humans. Standard diabetes medications have decades of large-scale trial evidence, regulatory approval, and pharmacovigilance that Pancragen does not.
Myth
Russian dietary-complex registration means Pancragen is approved as a diabetes medicine.
Reality
Russian Khavinson-affiliated capsule products are marketed as dietary peptide complexes, not as registered pharmaceuticals for diabetes management. This is a different regulatory category with lower evidence requirements than prescription-medicine approval and is not equivalent to Western drug approval.
Myth
Vladimir Khavinson won the Nobel Prize for peptide bioregulator research, validating the Pancragen claims.
Reality
He did not. Persistent online attributions to a Nobel Prize are inaccurate. The Khavinson program has published extensively, but the body of work has not received that level of recognition and core program claims have not been independently replicated in Western laboratories.
Myth
Because Pancragen targets the underlying cause of type-2 diabetes (beta-cell dysfunction), it is more curative than symptom-managing drugs.
Reality
This framing overstates the evidence. Mechanistic claims about beta-cell restoration come from in vitro and primate data within the Khavinson program; whether the same effect occurs durably in humans, at clinically meaningful magnitude, and without long-term safety problems has not been established. 'Treating the underlying cause' is an attractive narrative but not yet a demonstrated clinical reality for Pancragen.
Published Research
8 studiesCorrection of impaired glucose tolerance using tetrapeptide (Pancragen) in old female rhesus monkeys.
Impact of tetrapeptide pancragen on endocrine function of the pancreas in old monkeys.
Tetrapeptide stimulates functional activity of the pancreatic cells in aging.
Effects of pancragen on the differentiation of pancreatic cells during their ageing.
Peptides tissue-specifically stimulate cell differentiation during their aging.
Prospects of using pancragen for correction of metabolic disorders in elderly people.
The principal human clinical report for Pancragen — a small elderly type-2-diabetes study from the Khavinson group claiming improved glucose tolerance and reduced insulin resistance; the closest thing to an interventional trial in the Pancragen literature.
Study of biological activity of Lys-Glu-Asp-Trp-NH2 endogenous tetrapeptide.
Effect of pancragen on blood glucose level, capillary permeability and adhesion in rats with experimental diabetes mellitus.
Quick Facts
- Class
- Bioregulator Peptide
- Tier
- D
- Evidence
- Preliminary
- Safety
- Limited Data
- Updated
- Apr 2026
- Citations
- 8PubMed
Also known as
Tags
Peptide Families
Related Goals
Evidence Score
Clinical Trials
View Clinical TrialsLinks to ClinicalTrials.gov for reference. Listing does not imply endorsement.